Age-related macular degeneration (AMD) is one of the leading causes of blindness in elderly populations worldwide.^[@R1],[@R2]^ Results from recent epidemiologic studies indicate a similar prevalence of AMD among Asian and white populations: a systematic review and meta-analysis found pooled prevalence estimates of early and late AMD in Asian people of 6.8% and 0.56%, respectively, similar to the corresponding prevalence estimates in white people of 8.8% and 0.59%.^[@R3]^ However, because of rapidly aging populations in Asia, it has been estimated that more than half of all AMD cases are expected to be among Asians by 2040.^[@R4]^

There are a number of characteristics that distinguish Asian patients with neovascular AMD (nAMD) from white patients with nAMD, including a higher proportion of the polypoidal choroidal vasculopathy subtype of nAMD and a lower prevalence of retinal angiomatous proliferation.^[@R5]--[@R12]^ Differences in the occurrence of disease-susceptible genes have also been suggested.^[@R13],[@R14]^ However, other studies have suggested that the incidence, natural history, and risk factors of nAMD are similar between Asian and white people.^[@R15]--[@R19]^ Importantly, it is unclear whether ethnicity impacts treatment outcomes because no studies have directly compared treatment outcomes between these two groups.

Intravitreal injections of anti--vascular endothelial growth factor (VEGF) agents, such as ranibizumab and aflibercept, are now the standard of care for patients with nAMD.^[@R2],[@R20]^ However, most trials on nAMD have been conducted in white populations, and the efficacy and safety of anti-VEGF therapy in Asian patients with nAMD are less well investigated.^[@R21]^ Furthermore, there are currently no data on the relative efficacy and safety of ranibizumab versus intravitreal aflibercept in Asian patients presenting with nAMD.

The VIEW trials present a unique opportunity to evaluate the efficacy and safety of anti-VEGF therapy in Asian people, as these trials included a large number of patients recruited from Asian countries. In a subgroup analysis of Japanese patients in the VIEW trials, intravitreal aflibercept was found to be effective and well tolerated in Japanese patients, with 52-week outcomes similar to those in the overall VIEW 2 population.^[@R22]^ In this article, we report on a new post hoc subgroup analysis to evaluate, first, the longer-term efficacy and safety of intravitreal aflibercept compared with ranibizumab at 2 years (96 weeks) in all Asian patients with nAMD who were enrolled in the VIEW trials, and second, whether the treatment response for these agents is similar in Asian patients compared with that of white patients.

Methods {#s1}
=======

Study Design {#s1-1}
------------

The details of the VIEW trials ([clinicaltrials.gov](http://clinicaltrials.gov) NCT00509795 and NCT00637377) have been published previously.^[@R23],[@R24]^ In the Asia-Pacific region, sites were located in Japan (n = 15), South Korea (n = 6), Singapore (n = 3), India (n = 15), and Australia (n = 7). The studies were conducted according to the principles of the Declaration of Helsinki and the International Conference on Harmonisation. Protocols for the VIEW trials were prospectively approved by institutional review boards or ethics committees at each clinical site.

Participants and Treatments {#s1-2}
---------------------------

The Asian subpopulation analyzed here comprises all patients in Japan, South Korea, Singapore, India, and the subgroup of Asian patients in the United Kingdom and the United States. Race was defined based on participants\' and investigators\' declaration of listing race/ethnicity as "Asian" in the data collection form.

Patients with nAMD were randomized 1:1:1:1 to treatment with ranibizumab 0.5 mg monthly (Rq4) or intravitreal aflibercept 2 mg monthly (2q4), 0.5 mg monthly (0.5q4), or 2 mg every 2 months after 3 initial monthly doses (2q8). From Week 52 through Week 96, patients received their original dosing assignment using a capped pro re nata regimen with defined retreatment criteria and mandatory dosing at least every 12 weeks.

Outcome Measures {#s1-3}
----------------

The primary endpoint analysis of the VIEW trials was noninferiority of the intravitreal aflibercept regimens to ranibizumab in the proportion of patients maintaining vision at Week 52 (defined in the VIEW trials as losing \<15 Early Treatment Diabetic Retinopathy Study \[ETDRS\] letters). Prespecified secondary efficacy outcomes compared visual and anatomical changes from baseline to Week 52 among treatment groups. Efficacy endpoints evaluated after Week 52 were exploratory.

In this article, we evaluate functional and morphologic outcomes between treatment groups after 96 weeks, first in the Asian subpopulation and then between Asian and white patients enrolled in the VIEW trials.

Statistical Analyses {#s1-4}
--------------------

The analyses reported here are based on pooled 2-year data of the VIEW 1 and VIEW 2 trials. All efficacy analyses were conducted in the full analysis set, which included all randomized patients who received any study drug and had a baseline and at least one postbaseline best-corrected visual acuity (BCVA) assessment, and all safety analyses were conducted in the safety analysis set, which included all patients who received any study medication. The last observation carried forward approach was used to impute missing values. All statistical tests are exploratory and were performed 2-sided with a Type I error rate of 5%. Cochran--Mantel--Haenszel tests and analyses of covariance were used to compare frequencies and continuous variables, respectively. Given the post hoc nature of these analyses, all *P* values are nonconfirmatory. All analyses were adjusted by study. Comparisons between Asian and white patients were also adjusted by age to address baseline differences. Given the small and underpowered sample, the results of these post hoc analyses should be considered hypothesis generating.

Results {#s2}
=======

Patient Demographics, Disease Characteristics, and Disposition {#s2-1}
--------------------------------------------------------------

A total of 2,457 patients were randomized to treatment in the VIEW trials. Of the 2,412 patients who comprised the full analysis set, 2,044 (84.7%) were white and 269 (11.2%) were Asian (Rq4, n = 60; 2q4, n = 70; 0.5q4, n = 66; 2q8, n = 73) (Figure [1](#F1){ref-type="fig"}). The number of patients in other racial groups was too small for subgroup analysis.

![Patient disposition by race and treatment group in the VIEW trials. 0.5q4, intravitreal aflibercept 0.5 mg every 4 weeks; 2q4, intravitreal aflibercept 2 mg every 4 weeks; 2q8, intravitreal aflibercept 2 mg every 8 weeks after 3 initial monthly doses; FAS, full analysis set; Rq4, ranibizumab 0.5 mg every 4 weeks.](retina-39-537-g001){#F1}

Baseline demographics and disease characteristics were largely balanced across treatment groups within the Asian subpopulation, although the distribution of lesion types varied (Table [1](#T1){ref-type="table"}). The differences in baseline demographics between Asian and white patients were in age, sex, and lens status. The mean age in Asian patients was 69.4 years, whereas the mean age in white patients was 76.9 years. In addition, among Asian patients, the majority were male in all treatment groups, whereas among white patients, the majority were female in all treatment groups. Finally, the proportion of Asian patients with pseudophakia at baseline was 21.9% and in white patients it was 35.0%.

###### 

Baseline Demographics and Disease Characteristics

![](retina-39-537-g002)

Treatment Experience {#s2-2}
--------------------

Within the Asian subgroup, patients received, on average, 17.1, 15.5, 15.9, and 11.0 injections over 96 weeks and 4.8, 3.7, 4.0, and 3.8 injections during Weeks 52 through 96 in the Rq4, 2q4, 0.5q4, and 2q8 groups, respectively. Among white patients, mean injection frequencies were 16.5, 16.0, 16.3, and 11.2 injections over 96 weeks and 4.6, 4.0, 4.6, and 4.2 injections during Weeks 52 through 96 in the Rq4, 2q4, 0.5q4, and 2q8 groups, respectively.

Efficacy of Intravitreal Aflibercept and Ranibizumab in Asian Patients {#s2-3}
----------------------------------------------------------------------

At Week 96, a comparable proportion of Asian patients treated with intravitreal aflibercept achieved the primary endpoint of maintaining vision (i.e., loss of \<15 letters from baseline) compared with those treated with ranibizumab (Table [2](#T2){ref-type="table"}).

###### 

Differences in Efficacy Endpoints Between Intravitreal Aflibercept and Ranibizumab in Asian Patients With nAMD

![](retina-39-537-g003)

Mean BCVA increased across all treatment groups in the Asian subpopulation (Figure [2](#F2){ref-type="fig"}). There were no significant differences between treatment groups. At Week 96, the proportions of patients gaining ≥15 letters of vision were comparable across all treatment groups.

![Mean changes over 96 weeks in the VIEW trials. **A.** Best-corrected visual acuity in Asian patients. **B.** Best-corrected visual acuity in white patients. **C.** Central retinal thickness in Asian patients. **D.** Central retinal thickness in white patients. 0.5q4, intravitreal aflibercept 0.5 mg every 4 weeks; 2q4, intravitreal aflibercept 2 mg every 4 weeks; 2q8, intravitreal aflibercept 2 mg every 8 weeks after 3 initial monthly doses; ETDRS, early treatment diabetic retinopathy study; Rq4, ranibizumab 0.5 mg every 4 weeks.](retina-39-537-g004){#F2}

Central retinal thickness (CRT) on optical coherence tomography decreased from baseline across all treatment groups in the Asian subpopulation (Figure [2](#F2){ref-type="fig"}). The differences in decrease were nominally significant in favor of intravitreal aflibercept for 2q4 versus Rq4 and 2q8 versus Rq4 (*P* = 0.0075 and *P* = 0.0126, respectively).

A total of 166 (61.7%) Asian patients achieved a dry retina at Week 12 (i.e., after 3 initial monthly doses). The difference in the proportion of patients achieving a dry retina at Week 12 was nominally significant for 2q4 versus Rq4 (*P* \< 0.01). At Week 96, 149 (55.4%) Asian patients achieved dry retina. The difference in proportion of patients achieving dry retina at Week 96 was nominally significant for 2q4 versus Rq4 (*P* \< 0.01).

Mean choroidal neovascularization area also decreased across all treatment groups in the Asian subpopulation. There were no significant differences between treatment groups.

All treatment groups within the Asian subpopulation experienced improvements from baseline in mean total 25-item National Eye Institute Visual Function Questionnaire score. There were no significant differences between treatment groups.

Efficacy in Asian Patients Versus White Patients {#s2-4}
------------------------------------------------

Mean BCVA increased across all treatment groups in the white subpopulation (Figure [2](#F2){ref-type="fig"}). The mean gain in BCVA was numerically greater in white patients treated with intravitreal aflibercept 2q4 and 2q8 than in white patients treated with ranibizumab (Table [3](#T3){ref-type="table"}).

###### 

Differences in Efficacy Endpoints Between Asian and White Patients

![](retina-39-537-g005)

Although there were a few numerical differences seen in descriptive results comparing Asian and white patients (Figure [2](#F2){ref-type="fig"}), there were no differences when results were adjusted for age, except for a greater decrease in CRT among Asian patients in the intravitreal aflibercept groups (Table [3](#T3){ref-type="table"}).

When baseline lesion subtype was taken into account, some differences between Asian and white patients were observed (Figure [3](#F3){ref-type="fig"}), possibly because of fewer patients in the Asian subgroup. Specifically, among those with occult lesions in the 2q4 treatment group, a greater proportion of Asian patients maintained vision compared with white patients. Likewise, in those with minimally classic lesions in the 2q8 group, a greater proportion of Asian patients maintained vision compared with white patients. Finally, among patients with occult lesions in the 2q8 treatment group, decreases in CRT were greater in Asian patients compared with white patients.

![Efficacy endpoints by lesion type, Asian versus white patients. CI, confidence interval; n, number of patients with this outcome; N, total number of patients; 0.5q4, intravitreal aflibercept 0.5 mg every 4 weeks; 2q4, intravitreal aflibercept 2 mg every 4 weeks; 2q8, intravitreal aflibercept 2 mg every 8 weeks after three initial monthly doses; Rq4, ranibizumab 0.5 mg every 4 weeks.](retina-39-537-g006){#F3}

Safety {#s2-5}
------

The overall number of ocular serious adverse events (SAEs) was low in the VIEW trials. The most common SAEs among Asian patients were cataract and visual acuity reduced (n = 4 for both) and the most common SAEs among white patients were retinal hemorrhage and visual acuity reduced (n = 14 for both) (Table [4](#T4){ref-type="table"}).

###### 

Serious Ocular Adverse Events in the Study Eye and Antiplatelet Trialists\' Collaboration--Defined Arterial Thromboembolic Events in Asian and White Patients

![](retina-39-537-g007)

The overall proportion of patients with ocular SAEs and the proportion of patients with Antiplatelet Trialists\' Collaboration--defined arterial thromboembolic events were numerically higher in the white population versus the Asian population (Table [4](#T4){ref-type="table"}).

Safety analyses for the Asian subpopulation of the VIEW trials should be interpreted with caution, given fewer patients in each treatment group.

Discussion {#s3}
==========

We evaluated the long-term efficacy and safety of intravitreal aflibercept and ranibizumab for the treatment of nAMD in 269 Asian patients enrolled in the VIEW trials, and compared the outcomes in these Asian patients with those of white patients. In general, among the Asian population from the VIEW trials, patients in all treatment groups experienced visual and anatomical improvements after treatment with anti-VEGF therapy, with no differences between intravitreal aflibercept and ranibizumab. Furthermore, the outcomes in Asian patients were largely similar to those experienced by white patients. The frequencies of adverse events, including vascular events, were low among Asian patients and distributed evenly across treatment groups. These data emphasize two important findings: first, that the two anti-VEGF agents have long-term clinical effectiveness, safety, and value for Asian patients with nAMD, and second, that there are no appreciable differences in treatment response for Asian patients compared with white patients.

Our study included the largest group of Asian patients with nAMD enrolled in a clinical trial. Previous studies, including the Comparison of Age-related macular degeneration Treatment Trials (CATT)^[@R25]^ and a subgroup analysis of 84 Japanese patients in the VIEW trials,^[@R22]^ reported that mean BCVA at baseline has an impact on mean change in BCVA over the study period, with better baseline visual acuity associated with lesser gains in visual acuity. The results of the current analysis are consistent with those of the previous studies. In this study, Asian patients in the 0.5q4 treatment group of the VIEW trials had the lowest baseline BCVA (48.5 ETDRS letters) and the greatest unadjusted gains in visual acuity at Week 52 (12.2 ETDRS letters) and Week 96 (11.2 ETDRS letters) compared with the other treatment groups. This high improvement in BCVA may be explained by the relatively small sample size and imbalances in baseline characteristics (e.g., age, sex, and lens status), or because these patients had more room to gain in BCVA. In the 2q4 and 2q8 groups, trends in BCVA scores over 96 weeks were similar between Asian and white patients. Asian and white patients in the 2q4 group experienced a mean change of approximately 9 letters at Week 52 and approximately 8 letters at Week 96. Asian patients in the 2q8 group experienced unadjusted mean changes approximately 1 letter greater than white patients in the 2q8 group at both Weeks 52 and 96 (Figure [2](#F2){ref-type="fig"}).

Taking into account the difference in age distribution between the two patient subgroups, our analysis also suggests that the overall benefit of treatments of both intravitreal aflibercept and ranibizumab was similar between Asian and white patients in the VIEW trials. Several interesting differences between white and Asian patients were noted when lesion type was taken into account, reflecting results of other studies that showed ethnic differences in clinical nAMD subtypes.^[@R26]^ For example, in the subgroup of patients with minimally classic lesions treated with intravitreal aflibercept 2q8, a greater proportion of Asian patients maintained vision compared with white patients. Among patients with occult lesions in the same subgroup treated with intravitreal aflibercept 2q8, decreases in CRT were greater in Asian patients compared with white patients. These findings may indicate a potential role for lesion type as a predictor of treatment response to anti-VEGF therapy. However, these findings should be interpreted with caution. This is a subgroup analysis (lesion size) within a subgroup analysis (Asian patients vs. white patients) of the VIEW trials, the number of patients is not balanced in the compared lesion subgroups, and the described findings do not follow a consistent pattern. It is therefore possible that these findings could be due to chance. Whether these interesting differences between Asian and white patients reflect true ethnic differences in response to anti-VEGF therapy or whether they result from the inherent imbalance of sample sizes in this post hoc analysis would need to be determined using prospective randomized studies. These findings are consistent with the guidance of the International Conference on Harmonisation E5 report titled Ethnic Factors in the Acceptability of Foreign Clinical Data, that intravitreal aflibercept is insensitive to ethnic factors.

Limitations of this analysis should be taken into account. This is a post hoc analysis, and not a prespecified subgroup analysis, and these analyses were limited by smaller sample sizes in each subgroup, including lesion size subgroups. The effect of potential polypoidal choroidal vasculopathy subtype in some patients could not be analyzed. Nevertheless, results of two recent randomized trials of polypoidal choroidal vasculopathy (EVEREST II and PLANET) suggest that intravitreal aflibercept and ranibizumab monotherapy are safe and efficacious over 1 year (presented by Koh et al at the American Academy of Ophthalmology, November 2016 and by Lee et al at the Asia-Pacific Vitreoretinal Society, December 2016). Our subgroup analysis represents the largest Asian study of nAMD to date.

In conclusion, we conducted a post hoc analysis of the VIEW trials to address two clinically important questions: first, if anti-VEGF therapy with intravitreal aflibercept and ranibizumab is similarly efficacious and safe in Asian patients with nAMD, and second, if treatment outcomes are similar between Asian and white patients. We demonstrated that intravitreal aflibercept and ranibizumab are safe and effective in Asian patients with nAMD through 2 years (96 weeks). Despite differences in clinical disease presentation between Asian and white patients with nAMD, the magnitude of the benefits observed in both groups was comparable. The incidence of SAEs was consistent with the known safety profile of anti-VEGF therapy. This study clearly demonstrates the benefit of intravitreal anti-VEGF therapy for nAMD in Asian patients, with significant functional and morphologic benefits as seen in other pivotal trials.

T. Y. Wong reports grants, consultancy fees, honorarium, travel support, and speaker fees from Bayer and Novartis during the conduct of the study, and consultancy fees and travel support from Abbott, Allergan, Bayer, Genentech, Novartis, Roche, and Pfizer outside the submitted work. C. M. Gemmy Cheung reports grants, personal fees, and nonfinancial support from Bayer; grants, personal fees, and nonfinancial support from Novartis; and grants from Topcon and Roche outside the submitted work. T. Y. Y. Lai reports personal fees from Allergan and Bausch & Lomb and grants and personal fees from Bayer and Novartis Pharmaceuticals; and personal fees from Genentech outside the submitted work. W. K. Lee reports personal fees from Bayer, Novartis, Allergan, and Alcon outside the submitted work. Y. H. Yoon reports grants and personal fees from Allergan and Alcon; and grants and personal fees from Bayer, outside the submitted work. T. Iida reports personal fees from Bayer Yakuhin Ltd (Japan), grants and personal fees from Novartis Pharma K.K. (Japan) and Santen Pharmaceutical Co, Ltd (Japan), and grants from Nidek outside the submitted work. C. Tueckmantel and O. Sowade are employees of Bayer AG. Y. Ogura reports personal fees from Bayer during the conduct of the study; personal fees from Novartis, grants and personal fees from Alcon, Santen, Senju, and HOYA; personal fees from Topcon, Wakamoto, and Kowa; and grants from Pfizer, outside the submitted work. The remaining author has no conflicting interests to disclose.

The VIEW 1 and VIEW 2 trials were supported by Bayer and Regeneron Pharmaceuticals, Inc.

The study funders had a role in study design, collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the article for publication. Medical writing assistance was provided by Corey Eagan, MPH, of PAREXEL, and was funded by Bayer.

Conflict of interest statement has been moved to acknowledgments section.
